A first-in-human, randomised, placebo-controlled, multi-centre Phase I/IIa study evaluating the safety and clinical activity of ITOP1 administered intravenously to 60 adults with resectable oesophageal adenocarcinoma

Status: Not yet recruiting

Phase of Trial: Phase I/II

Latest Information Update: 15 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ITOP 1 (Primary) ; Antineoplastics
Indications Adenocarcinoma; Oesophageal cancer
Focus Adverse reactions; First in man
Acronyms VISTA

Most Recent Events

15 Nov 2024 New trial record
08 Nov 2024 According to Infinitopes media release, overall design and purpose of trial will be presented at the Society for Immunotherapy of Cancer (SITC) 2024
01 Nov 2024 Trial design presented in Journal for ImmunoTherapy of Cancer

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight